This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.
Background: We used 188Re-lanreotide to determine its radiopharmaceutical parameters in a
model of Wistar rats with induced hepatocellular carcinoma, aft er a single intravenous dose. Th e
rat model is useful to determine the pharmacokinetic parameters and the tumor/organ ratios
of 188Re-lanreotide to be used for calculating the personal dose following the methodology
MIRDOSE and later in the diagnosis and therapy of cancer.
Objetive: We used 188Re-lanreotide to determine radiopharmaceutical parameters in a model
in rats Wistar.
Methods: 188Re labeled by a modifi ed direct method. AS-30D hepatoma cells were obtained
from ascites of a Wistar rat with hepatoma. Healthy and tumor induced hepatocellular carcinoma
Wistar rats were used for distribution and radiopharmacokinetic studies. 188Re-lanreotide, ≈1.8
MBq in 0.1 mL was injected in the peritoneal cavity and in the dorsal left side of healthy rats. Th e
rats were sacrifi ced at 0.083, 0.25, 0.5, 1.16, 3 and 24 h post injection. Th e activity (%IA/g) of all
the blood samples in the following times: 0.25, 0.5, 1.1, 3, 5, 8, 12, 15, 18, and 24 h for healthy
rats and 0.25, 0.5, 1.16, 3, and 24 h for hepatoma induced rats.
Results: Th e radiopharmacokinetic parameters were calculated following a two-compartment,
fi rst-order elimination model of 188Re-lanreotide in healthy rats and for rats with induced tumor
using the WinNonlin program.
Conclusion: A pharmacokinetic profi le of 188Re-lanreotide in healthy and hepatoma tumor
induced rats follow model two-compartment. With mean residence time and the mean half life
we will be calculate the therapeutic dose following MIRDOSE methodology
Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals